MS Briefs

Trait Conscientiousness and SDMT Decline in MS

Mult Scler; ePub 2019 Jan 7; Fuchs, et al


 

Higher baseline trait conscientiousness predicts slower rates of longitudinal cognitive decline in multiple sclerosis (MS), according to a recent study. Researchers conducted a retrospective analysis of 531 patients with MS whose data were gleaned from a multi-study database, aggregated over 16 years. Linear mixed effects modeling was applied to estimate the average rate of decline on Symbol Digit Modalities Test (SDMT) performance and to predict rates of decline using baseline clinical variables. They found:

  • Participants exhibited an average estimated decline of 0.22 SDMT raw-score points/year.
  • There was a significant main effect of time from baseline ( t = −2.78), test form ( t = 2.13), disease course ( t = 2.91), age ( t = −2.76), sex ( t = −2.71), subjective cognitive impairment ( t = −2.00), premorbid verbal intelligence ( t = 5.14), and trait Conscientiousness ( t = 2.69).
  • A significant interaction emerged for Conscientiousness and time from baseline ( t = 2.57).

Fuchs TA, Wojcik C, Wilding GE, et al. Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis. [Published online ahead of print January 7, 2019]. Mult Scler . doi:10.1177%2F1352458518820272.

Recommended Reading

Does rituximab delay disability progression in patients with secondary progressive MS?
ICYMI Multiple Sclerosis
Daclizumab beta may be superior to interferon beta on MS disability progression
ICYMI Multiple Sclerosis
Interferon Beta May Not Affect Pregnancy Outcomes in MS
ICYMI Multiple Sclerosis
Autologous Hematopoietic Stem Cells May Treat Aggressive MS Effectively
ICYMI Multiple Sclerosis
DMTs, stem cell transplants both reduce disease progression in MS
ICYMI Multiple Sclerosis
Examining Pseudobulbar Affect in Multiple Sclerosis
ICYMI Multiple Sclerosis
Body Composition, Disability in People with MS
ICYMI Multiple Sclerosis
Core Temperature Not Elevated at Rest in RRMS
ICYMI Multiple Sclerosis
Interview with Joseph R. Berger, MD, on the Financial Contribution of the MS Specialist
ICYMI Multiple Sclerosis
Global Burden of Multiple Sclerosis, 1990-2018
ICYMI Multiple Sclerosis